Decreased expression of α2,8 sialyltransferase and increased expression of β1,4 N-acetylgalactosaminyltransferase in gastrointestinal cancers

Yasuhiro Koh, Takuya Tsunoda, Makoto Iwahashi, Hiroki Yamaue, Kiwao Ishimoto, Hiroshi Tanimura, Hisao Fukumoto, Takashi Nakamura, Yasuaki Tatsumi, Mikiko Shimizu, Nagahiro Saijo, Kazuto Nishio

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Gangliosides such as GD3, GM2, and GD2 are abundantly expressed on the cell surfaces of various malignant cells, suggesting the potential for anti-ganglioside antibody therapy for tumors. Anti-ganglioside GD2 antibody treatment is currently undergoing clinical trials for melanoma and neuroblastoma. We previously reported high in vivo antitumor effects of anti-GM2 ganglioside antibody against lung cancer. To determine whether anti-GM2 antibody may be clinically indicated for gastrointestinal cancers, we evaluated the mRNA expression of α2,8 sialyltransferase, a GD3 synthase, and β1,4 N-acetylgalactosaminyltransferase (β1,4 N-acetylga lactosaminyltransferase (β1,4 GaINAc-T), a GM2/GD2 synthase, in gastrointestinal cancers. We performed modified semi-quantitative RT-PCR, which reduces complexity incidental to radiolabeling on samples taken from small surgically removed clinical specimens. Stomach (19/22) and colorectal (21/30) cancers showed decreased expression of α2,8 sialyltransferase as compared with respective normal tissues (P > 0.05). In contrast, increased expression of β1,4 Gal-NAc-T was detected in both types of tumors. Clinicopathological analysis revealed significantly higher expression level of α2,8 sialyltransferase in the poorly differentiated than in the well-differentiated stomach cancer group (P > 0.05). Furthermore, the expression level of α2,8 sialyltransferase was significantly decreased in male as compared with female colorectal cancer patients (P > 0.05). These results suggest that expression level of GM2 ganglioside is elevated in gastrointestinal cancer, and that anti-GM2 antibody may be applicable to its treatment.

Original languageEnglish
Pages (from-to)196-200
Number of pages5
JournalExperimental Biology and Medicine
Volume227
Issue number3
Publication statusPublished - 2002 Mar
Externally publishedYes

Fingerprint

N-Acetylgalactosaminyltransferases
Sialyltransferases
Gastrointestinal Neoplasms
(N-acetylneuraminyl)-galactosylglucosylceramide N-acetylgalactosaminyltransferase
G(M2) Ganglioside
Anti-Idiotypic Antibodies
Antibodies
Gangliosides
Tumors
Neoplasms
Neuroblastoma
Stomach Neoplasms
Colorectal Neoplasms
Melanoma
Lung Neoplasms
Stomach
Therapeutics
Clinical Trials
Polymerase Chain Reaction
Messenger RNA

Keywords

  • α2,8 sialyltransferase
  • β1,4 N-acetylgalactosaminyltransferase
  • Ganglioside
  • Gastrointestinal cancer

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Koh, Y., Tsunoda, T., Iwahashi, M., Yamaue, H., Ishimoto, K., Tanimura, H., ... Nishio, K. (2002). Decreased expression of α2,8 sialyltransferase and increased expression of β1,4 N-acetylgalactosaminyltransferase in gastrointestinal cancers. Experimental Biology and Medicine, 227(3), 196-200.

Decreased expression of α2,8 sialyltransferase and increased expression of β1,4 N-acetylgalactosaminyltransferase in gastrointestinal cancers. / Koh, Yasuhiro; Tsunoda, Takuya; Iwahashi, Makoto; Yamaue, Hiroki; Ishimoto, Kiwao; Tanimura, Hiroshi; Fukumoto, Hisao; Nakamura, Takashi; Tatsumi, Yasuaki; Shimizu, Mikiko; Saijo, Nagahiro; Nishio, Kazuto.

In: Experimental Biology and Medicine, Vol. 227, No. 3, 03.2002, p. 196-200.

Research output: Contribution to journalArticle

Koh, Y, Tsunoda, T, Iwahashi, M, Yamaue, H, Ishimoto, K, Tanimura, H, Fukumoto, H, Nakamura, T, Tatsumi, Y, Shimizu, M, Saijo, N & Nishio, K 2002, 'Decreased expression of α2,8 sialyltransferase and increased expression of β1,4 N-acetylgalactosaminyltransferase in gastrointestinal cancers', Experimental Biology and Medicine, vol. 227, no. 3, pp. 196-200.
Koh, Yasuhiro ; Tsunoda, Takuya ; Iwahashi, Makoto ; Yamaue, Hiroki ; Ishimoto, Kiwao ; Tanimura, Hiroshi ; Fukumoto, Hisao ; Nakamura, Takashi ; Tatsumi, Yasuaki ; Shimizu, Mikiko ; Saijo, Nagahiro ; Nishio, Kazuto. / Decreased expression of α2,8 sialyltransferase and increased expression of β1,4 N-acetylgalactosaminyltransferase in gastrointestinal cancers. In: Experimental Biology and Medicine. 2002 ; Vol. 227, No. 3. pp. 196-200.
@article{2d5bd2954c7542be8854055d5166f869,
title = "Decreased expression of α2,8 sialyltransferase and increased expression of β1,4 N-acetylgalactosaminyltransferase in gastrointestinal cancers",
abstract = "Gangliosides such as GD3, GM2, and GD2 are abundantly expressed on the cell surfaces of various malignant cells, suggesting the potential for anti-ganglioside antibody therapy for tumors. Anti-ganglioside GD2 antibody treatment is currently undergoing clinical trials for melanoma and neuroblastoma. We previously reported high in vivo antitumor effects of anti-GM2 ganglioside antibody against lung cancer. To determine whether anti-GM2 antibody may be clinically indicated for gastrointestinal cancers, we evaluated the mRNA expression of α2,8 sialyltransferase, a GD3 synthase, and β1,4 N-acetylgalactosaminyltransferase (β1,4 N-acetylga lactosaminyltransferase (β1,4 GaINAc-T), a GM2/GD2 synthase, in gastrointestinal cancers. We performed modified semi-quantitative RT-PCR, which reduces complexity incidental to radiolabeling on samples taken from small surgically removed clinical specimens. Stomach (19/22) and colorectal (21/30) cancers showed decreased expression of α2,8 sialyltransferase as compared with respective normal tissues (P > 0.05). In contrast, increased expression of β1,4 Gal-NAc-T was detected in both types of tumors. Clinicopathological analysis revealed significantly higher expression level of α2,8 sialyltransferase in the poorly differentiated than in the well-differentiated stomach cancer group (P > 0.05). Furthermore, the expression level of α2,8 sialyltransferase was significantly decreased in male as compared with female colorectal cancer patients (P > 0.05). These results suggest that expression level of GM2 ganglioside is elevated in gastrointestinal cancer, and that anti-GM2 antibody may be applicable to its treatment.",
keywords = "α2,8 sialyltransferase, β1,4 N-acetylgalactosaminyltransferase, Ganglioside, Gastrointestinal cancer",
author = "Yasuhiro Koh and Takuya Tsunoda and Makoto Iwahashi and Hiroki Yamaue and Kiwao Ishimoto and Hiroshi Tanimura and Hisao Fukumoto and Takashi Nakamura and Yasuaki Tatsumi and Mikiko Shimizu and Nagahiro Saijo and Kazuto Nishio",
year = "2002",
month = "3",
language = "English",
volume = "227",
pages = "196--200",
journal = "Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.)",
issn = "0037-9727",
publisher = "Society for Experimental Biology and Medicine",
number = "3",

}

TY - JOUR

T1 - Decreased expression of α2,8 sialyltransferase and increased expression of β1,4 N-acetylgalactosaminyltransferase in gastrointestinal cancers

AU - Koh, Yasuhiro

AU - Tsunoda, Takuya

AU - Iwahashi, Makoto

AU - Yamaue, Hiroki

AU - Ishimoto, Kiwao

AU - Tanimura, Hiroshi

AU - Fukumoto, Hisao

AU - Nakamura, Takashi

AU - Tatsumi, Yasuaki

AU - Shimizu, Mikiko

AU - Saijo, Nagahiro

AU - Nishio, Kazuto

PY - 2002/3

Y1 - 2002/3

N2 - Gangliosides such as GD3, GM2, and GD2 are abundantly expressed on the cell surfaces of various malignant cells, suggesting the potential for anti-ganglioside antibody therapy for tumors. Anti-ganglioside GD2 antibody treatment is currently undergoing clinical trials for melanoma and neuroblastoma. We previously reported high in vivo antitumor effects of anti-GM2 ganglioside antibody against lung cancer. To determine whether anti-GM2 antibody may be clinically indicated for gastrointestinal cancers, we evaluated the mRNA expression of α2,8 sialyltransferase, a GD3 synthase, and β1,4 N-acetylgalactosaminyltransferase (β1,4 N-acetylga lactosaminyltransferase (β1,4 GaINAc-T), a GM2/GD2 synthase, in gastrointestinal cancers. We performed modified semi-quantitative RT-PCR, which reduces complexity incidental to radiolabeling on samples taken from small surgically removed clinical specimens. Stomach (19/22) and colorectal (21/30) cancers showed decreased expression of α2,8 sialyltransferase as compared with respective normal tissues (P > 0.05). In contrast, increased expression of β1,4 Gal-NAc-T was detected in both types of tumors. Clinicopathological analysis revealed significantly higher expression level of α2,8 sialyltransferase in the poorly differentiated than in the well-differentiated stomach cancer group (P > 0.05). Furthermore, the expression level of α2,8 sialyltransferase was significantly decreased in male as compared with female colorectal cancer patients (P > 0.05). These results suggest that expression level of GM2 ganglioside is elevated in gastrointestinal cancer, and that anti-GM2 antibody may be applicable to its treatment.

AB - Gangliosides such as GD3, GM2, and GD2 are abundantly expressed on the cell surfaces of various malignant cells, suggesting the potential for anti-ganglioside antibody therapy for tumors. Anti-ganglioside GD2 antibody treatment is currently undergoing clinical trials for melanoma and neuroblastoma. We previously reported high in vivo antitumor effects of anti-GM2 ganglioside antibody against lung cancer. To determine whether anti-GM2 antibody may be clinically indicated for gastrointestinal cancers, we evaluated the mRNA expression of α2,8 sialyltransferase, a GD3 synthase, and β1,4 N-acetylgalactosaminyltransferase (β1,4 N-acetylga lactosaminyltransferase (β1,4 GaINAc-T), a GM2/GD2 synthase, in gastrointestinal cancers. We performed modified semi-quantitative RT-PCR, which reduces complexity incidental to radiolabeling on samples taken from small surgically removed clinical specimens. Stomach (19/22) and colorectal (21/30) cancers showed decreased expression of α2,8 sialyltransferase as compared with respective normal tissues (P > 0.05). In contrast, increased expression of β1,4 Gal-NAc-T was detected in both types of tumors. Clinicopathological analysis revealed significantly higher expression level of α2,8 sialyltransferase in the poorly differentiated than in the well-differentiated stomach cancer group (P > 0.05). Furthermore, the expression level of α2,8 sialyltransferase was significantly decreased in male as compared with female colorectal cancer patients (P > 0.05). These results suggest that expression level of GM2 ganglioside is elevated in gastrointestinal cancer, and that anti-GM2 antibody may be applicable to its treatment.

KW - α2,8 sialyltransferase

KW - β1,4 N-acetylgalactosaminyltransferase

KW - Ganglioside

KW - Gastrointestinal cancer

UR - http://www.scopus.com/inward/record.url?scp=0036514174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036514174&partnerID=8YFLogxK

M3 - Article

C2 - 11856818

AN - SCOPUS:0036514174

VL - 227

SP - 196

EP - 200

JO - Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.)

JF - Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.)

SN - 0037-9727

IS - 3

ER -